You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

Drug Price Trends for GENGRAF


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GENGRAF

Average Pharmacy Cost for GENGRAF

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GENGRAF 100 MG CAPSULE 00074-3109-32 7.06777 EACH 2025-01-02
GENGRAF 25 MG CAPSULE 00074-3108-32 1.77660 EACH 2025-01-02
GENGRAF 100 MG CAPSULE 00074-3109-32 6.73134 EACH 2024-12-18
GENGRAF 25 MG CAPSULE 00074-3108-32 1.69191 EACH 2024-12-18
GENGRAF 25 MG CAPSULE 00074-3108-32 1.68950 EACH 2024-11-20
GENGRAF 100 MG CAPSULE 00074-3109-32 6.72578 EACH 2024-11-20
GENGRAF 25 MG CAPSULE 00074-3108-32 1.68950 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Gengraf (Cyclosporine)

Introduction to Gengraf (Cyclosporine)

Gengraf, a brand name for the drug cyclosporine, is a calcineurin inhibitor used in various medical conditions, including organ transplant rejection prophylaxis, psoriasis, and rheumatoid arthritis. Understanding the market dynamics and price projections for Gengraf is crucial for both healthcare providers and patients.

Market Size and Growth

The cyclosporine drugs market, which includes Gengraf, is anticipated to grow at a moderate pace. The market is expected to register a Compound Annual Growth Rate (CAGR) of 4.1% over the forecast period (2024-2029)[1].

Key Drivers of Market Growth

Increasing Prevalence of Rheumatoid Arthritis

One of the primary drivers of the cyclosporine market is the rising prevalence of rheumatoid arthritis. According to a report by Nature Reviews Rheumatology, the prevalence of rheumatoid arthritis is increasing due to factors such as genetic predisposition, environmental exposures, demographics, socioeconomic status, and disease reporting. This increase in prevalence directly boosts the demand for cyclosporine, a key medication in managing rheumatoid arthritis[1].

Organ Transplantation

Cyclosporine is also widely used in organ transplantation to prevent rejection. The growing number of organ transplants, particularly in regions promoting medical tourism like the Asia-Pacific, contributes to the market growth of immunosuppressant drugs, including cyclosporine[4].

Regional Market Analysis

North America

North America currently holds the largest market share in the cyclosporine drugs market. This dominance is attributed to the high incidence of chronic diseases, advanced healthcare infrastructure, and significant spending on healthcare in this region[1].

Asia-Pacific

The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This growth is driven by the increasing prevalence of chronic diseases, growing medical tourism, and improving healthcare infrastructure in countries like India and China[1].

Competitive Landscape

The market for cyclosporine is competitive, with several major players involved. Key companies include AbbVie Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Santen Pharmaceutical Co., Ltd. These companies are continuously working on strategic initiatives to enhance their market presence and develop new formulations of cyclosporine[1].

Price Analysis

Current Pricing

The cost of Gengraf varies based on the dosage and form of the medication. For instance, the price for a supply of 30 capsules of Gengraf modified 25 mg oral capsule is around $23, while the 100 mg oral capsule costs approximately $58.96 for 30 capsules. The oral liquid form of Gengraf (100 mg/mL) costs about $105.36 for 50 milliliters[5].

Generic Versions

A generic version of cyclosporine is available, which can significantly reduce the cost. For example, the generic version of cyclosporine can cost as low as $22.70 for 30 capsules of the 25 mg dosage[5].

Coupons, Copay Cards, and Rebates

To make Gengraf more affordable, various coupons, copay cards, and rebates are available. These offers can be obtained through the manufacturer's website, medical professionals, or other healthcare resources[5].

Impact of COVID-19

The COVID-19 pandemic had a mixed impact on the cyclosporine market. Initially, there was an increased interest in cyclosporine as a potential treatment for COVID-19, but clinical trials were ultimately terminated due to futility. This led to a temporary decrease in demand for cyclosporine for COVID-19 treatment, which had unfavorable consequences in the short term[1].

Price Projections

Given the expected growth in the cyclosporine market, prices are likely to remain stable or see a moderate increase. Here are some key points to consider:

  • Generic Competition: The availability of generic versions of cyclosporine will continue to put downward pressure on prices, making the medication more affordable for patients.
  • Market Growth: The increasing prevalence of rheumatoid arthritis and the growing number of organ transplants will drive demand, potentially stabilizing or slightly increasing prices.
  • Regional Dynamics: The Asia-Pacific region's growth is expected to influence global pricing trends, with potential price reductions due to increased competition and market expansion.

Key Takeaways

  • The cyclosporine drugs market, including Gengraf, is expected to grow at a CAGR of 4.1% from 2024 to 2029.
  • The rising prevalence of rheumatoid arthritis and the increasing number of organ transplants are key drivers of market growth.
  • North America holds the largest market share, while the Asia-Pacific region is expected to grow at the highest CAGR.
  • Generic versions of cyclosporine are available, significantly reducing costs.
  • Various coupons, copay cards, and rebates are available to make Gengraf more affordable.

FAQs

What is the current market size of the cyclosporine drugs market?

The cyclosporine drugs market is projected to register a CAGR of 4.10% during the forecast period (2024-2029), but the exact current market size is not specified in the available data.

Who are the major players in the cyclosporine drugs market?

Major players include AbbVie Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Santen Pharmaceutical Co., Ltd.[1].

What are the primary uses of Gengraf (cyclosporine)?

Gengraf is used for organ transplant rejection prophylaxis, psoriasis, and rheumatoid arthritis[5].

How has the COVID-19 pandemic affected the cyclosporine market?

The COVID-19 pandemic initially saw increased interest in cyclosporine as a potential treatment, but clinical trials were terminated due to futility, leading to a temporary decrease in demand[1].

Are there any generic versions of Gengraf available?

Yes, generic versions of cyclosporine are available, which can significantly reduce the cost of the medication[5].

What regions are expected to drive the growth of the cyclosporine market?

North America currently holds the largest market share, while the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period[1].

Sources

  1. Mordor Intelligence: Cyclosporine Drugs Market - Size, Share & Manufacturers[1].
  2. California Department of Insurance: Large Group Aggregate Rate Data Report[2].
  3. Mordor Intelligence: Generic Drugs Market - Forecast & Outlook[3].
  4. Allied Market Research: Organ Transplant Immunosuppressant Drugs Market[4].
  5. Drugs.com: Gengraf Prices, Coupons, Copay Cards & Patient Assistance[5].

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.